190 related articles for article (PubMed ID: 15198894)
1. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
2. [Exploration of high expressions of retroviral vectors containing hFIX minigene in murine myoblast cells].
Hou J; Wang J; Min B
Zhonghua Xue Ye Xue Za Zhi; 2001 Mar; 22(3):121-4. PubMed ID: 11877060
[TBL] [Abstract][Full Text] [Related]
3. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
Yao SN; Smith KJ; Kurachi K
Gene Ther; 1994 Mar; 1(2):99-107. PubMed ID: 7584074
[TBL] [Abstract][Full Text] [Related]
4. Construction and high expression of retroviral vector with human clotting factor IX cDNA in vitro.
Lu D; Qiu X; Zheng B; Qiu X; Xue J
Sci China B; 1995 Jun; 38(6):705-12. PubMed ID: 7626200
[TBL] [Abstract][Full Text] [Related]
5. [Splicing and stability of intron in the expression retroviral vector with human clotting factor IX].
Xing YN; Lu DR; Gao XB; Qiu XF; Xue JL
Yi Chuan Xue Bao; 1998 Dec; 25(6):471-7. PubMed ID: 10465892
[TBL] [Abstract][Full Text] [Related]
6. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.
Wang JM; Zheng H; Sugahara Y; Tan J; Yao SN; Olson E; Kurachi K
Hum Gene Ther; 1996 Sep; 7(14):1743-56. PubMed ID: 8886845
[TBL] [Abstract][Full Text] [Related]
7. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer.
Larochelle N; Lochmüller H; Zhao J; Jani A; Hallauer P; Hastings KE; Massie B; Prescott S; Petrof BJ; Karpati G; Nalbantoglu J
Gene Ther; 1997 May; 4(5):465-72. PubMed ID: 9274724
[TBL] [Abstract][Full Text] [Related]
8. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo.
Park F; Kay MA
Mol Ther; 2001 Sep; 4(3):164-73. PubMed ID: 11545606
[TBL] [Abstract][Full Text] [Related]
9. Comparison of promoter region constructs for in vivo intramuscular expression.
Fabre EE; Bigey P; Orsini C; Scherman D
J Gene Med; 2006 May; 8(5):636-45. PubMed ID: 16477670
[TBL] [Abstract][Full Text] [Related]
10. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.
Chao H; Liu Y; Rabinowitz J; Li C; Samulski RJ; Walsh CE
Mol Ther; 2000 Dec; 2(6):619-23. PubMed ID: 11124063
[TBL] [Abstract][Full Text] [Related]
11. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
12. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
Tabotta W; Klein D; Hohenadl C; Salmons B; Günzburg WH
J Gene Med; 2001; 3(5):418-26. PubMed ID: 11601755
[TBL] [Abstract][Full Text] [Related]
13. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system.
Wahlfors JJ; Morgan RA
Hum Gene Ther; 1999 May; 10(7):1197-206. PubMed ID: 10340551
[TBL] [Abstract][Full Text] [Related]
14. High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors.
Dai YF; Qiu XF; Xue JL; Liu ZD
Sci China B; 1992 Feb; 35(2):183-93. PubMed ID: 1581003
[TBL] [Abstract][Full Text] [Related]
15. Stage I clinical trial of gene therapy for hemophilia B.
Lu DR; Zhou JM; Zheng B; Qiu XF; Xue JL; Wang JM; Meng PL; Han FL; Ming BH; Wang XP
Sci China B; 1993 Nov; 36(11):1342-51. PubMed ID: 8142023
[TBL] [Abstract][Full Text] [Related]
16. Increment of hFIX expression with endogenous intron 1 in vitro.
Zheng B; Qiu XY; Tan M; Xing YN; Lo D; Xue JL; Qiu XF
Cell Res; 1997 Jun; 7(1):21-9. PubMed ID: 9261559
[TBL] [Abstract][Full Text] [Related]
17. Differentiation-specific enhancer activity in transduced keratinocytes: a model for epidermal gene therapy.
Page SM; Brownlee GG
Gene Ther; 1998 Mar; 5(3):394-402. PubMed ID: 9614560
[TBL] [Abstract][Full Text] [Related]
18. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
19. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
20. Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient.
Zhou JM; Dai YF; Qiu XF; Hou GY; Akira Y; Xue JL
Sci China B; 1993 Sep; 36(9):1082-92. PubMed ID: 8274202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
